Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SB Aquafresh 17% Sales Increase Freshens Up Second Quarter Results

This article was originally published in The Tan Sheet

Executive Summary

"Outstanding" U.S. activity by the Aquafresh brand in the second quarter contributed to a 17% spike in worldwide sales for the line and an 8% rise in global oral care sales to $255 mil., SmithKline Beecham CEO Jean-Paul Garnier, PhD, announced during a July 25 conference call.

You may also be interested in...



Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.

Aquafresh Gum, Lozenges Carry "For Oral Care - Anytime, Anywhere" Tagline

SmithKline Beecham is moving its Aquafresh brand beyond the traditional dentrifice category into what appears to be the confectionary market.

SmithKline Clear NicoDerm CQ Latest Effort Against Private Label Rivals

The introduction of Clear NicoDerm CQ Patch will attract a substantial number of first-time users - especially among minority populations - to the smoking cessation category, marketer SmithKline Beecham predicted based on recent consumer research.

Related Content

Topics

UsernamePublicRestriction

Register

PS091496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel